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Abstract
To assess the potential of native Envelope glycoprotein (Env) trimers as neutralizing antibody vaccines, we immunized guinea pigs with three
types of VLPs and soluble gp120. Particles included “SOS-VLPs” (bearing disulfide-shackled functional trimers), “UNC-VLPs” (bearing
uncleaved nonfunctional Env) and “naked VLPs” (bearing no Env). The SOS-VLPs were found to have a density of about 27 native trimers per
particle, approximately twice that of live inactivated HIV-1 preparations. As immunogens, UNC- and SOS-VLP rapidly elicited anti-gp120
antibodies focused on the V3 loop and the gp120 coreceptor binding site. Reactivity to the gp41 immunodominant domain was absent in
SOS-VLP sera, presumably because gp120–gp41 association is stabilized, effectively covering this epitope. Gp120-immune sera reacted with the
receptor binding sites of gp120 and were less focused on the V3 loop. Some Env-VLP sera neutralized primary isolates at modest titers. The
measurement of neutralization was found to be affected by the cell lines used. Depending on the assay particulars, non-Env specific antibodies in
VLP sera could enhance infection, or nonspecifically neutralize. However, a neutralization assay using TZM-BL cells was essentially clear of
these effects. We also describe a native trimer binding assay to confirm neutralization activity in a manner that completely eliminates nonspecific
effects. Overall, our data suggests that Env-VLP sera were primarily focused on nonfunctional forms of Env on VLP surfaces, possibly gp120/
gp41 monomers and not the trimers. Therefore, to make progress toward a more effective VLP-based vaccine, we will need to find ways to refocus
the attention of B cells on native trimers.
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A vaccine is desperately needed to prevent the spread of
human immunodeficiency virus type 1 (HIV-1) (Garber et al.,
2004; Koff et al., 2007; Tramont and Johnston, 2003). It is
likely that a potent and broadly reactive neutralizing antibody
(nAb) response will be a crucial component of effective vaccine
immunity to HIV-1. However, despite the considerable
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toward an immunogen able to elicit such a response.
NAbs are thought to target envelope glycoprotein (Env)
spikes on HIV-1 surfaces, thereby inhibiting entry into
susceptible cells. Functional Env spikes consist of noncova-
lently associated trimers of gp120/gp41 heterodimers (Earl et
al., 1990). The gp120 moiety mediates binding to target cell
receptors, triggering gp41-mediated fusion and entry. As the
presumptive targets of neutralization, logic has fueled the
hypothesis that authentic Env trimers might be able to elicit
nAbs in a vaccine setting (Emini and Koff, 2004; Koff et al.,
2007; Tramont and Johnston, 2003). However, a major
stumbling block for vaccinologists has been that authentic
trimers are technically challenging to produce in a purified
form. A number of groups have expressed soluble recombi-
nant trimers that resemble the native structure to varying
degrees (Beddows et al., 2005, 2007; Binley et al., 2000;
Chakrabarti et al., 2002; Earl et al., 2001; Farzan et al., 1998;
Li et al., 2006; Sanders et al., 2002b; Srivastava et al., 2002;
VanCott et al., 1997; Yang et al., 2000). Challenges include
optimizing the inefficient gp120/gp41 cleavage process
(Yamshchikov et al., 1995) and stabilizing the weak inter-
subunit associations within trimers (Staropoli et al., 2000).
Gp120/gp41 processing can be enhanced by optimizing the
substrate sequence and by co-expressing furin (Binley et al.,
2002; McKenna et al., 2003; Yamshchikov et al., 1995).
Gp120–gp41 association can be stabilized by appropriately
positioned cysteine mutations to form an intermolecular
disulfide bond (Binley et al., 2000). These advances led to
a recombinant Env glycoprotein, termed gp140SOS (Binley et
al., 2000). The later observation that gp140SOS trimers readily
dissociate into monomers presented a further challenge
(Schulke et al., 2002). One solution involved introducing a
helix-breaking mutation in gp41, to make mutant trimers
termed gp140SOSIP (Beddows et al., 2005, 2007; Sanders et
al., 2002b). An alternative solution may be to express trimers
in situ on membrane surfaces, perhaps imparting stability
without the need for additional mutations.
Env can be presented on membranes in several ways,
including liposomes, inactivated viruses, virus-like particles
(VLPs) and pseudovirions (Grovit-Ferbas et al., 2000; Grund-
ner et al., 2002; Race et al., 1995; Rossio et al., 1998).
Particulate vaccines have a long history of success for a variety
of diseases, including those caused by rotavirus (Conner et al.,
1996), norwalk virus (Harrington et al., 2002), tick-borne
encephalitis virus (Aberle et al., 1999) and HCV (Issel et al.,
1992). Successful clinical trials of human papilloma VLPs have
led to recent FDA approval (Evans et al., 2001; Koutsky et al.,
2002). There are, of course, even better known examples of
particulate vaccines, of which Salk's inactivated polio vaccine
and the hepatitis B vaccines are perhaps the best examples
(Salk, 1977; Valenzuela et al., 1982). The success of these
immunogens may derive from an ability to prime T-cells (Haffar
et al., 1991; Wagner et al., 1998), and to rapidly induce high titer
Ab responses, even sometimes in the absence of adjuvant (Lorin
et al., 2004; Wagner et al., 1998). Another key factor in their
success may derive from the authentic presentation of surfacestructures (Aberle et al., 1999; Beddows et al., 2005; Edinger
et al., 2000).
Particulate vaccine candidates for HIV-1 have been
described by many groups (Buonaguro et al., 2005; Evans et
al., 2005; Grovit-Ferbas et al., 2000; Haffar et al., 1991;
Hammonds et al., 2003; Katz and Moss, 1997; Lifson et al.,
2004; McBurney et al., 2007; McKenna et al., 2003; Montefiori
et al., 2001; Vzorov et al., 1999; Wagner et al., 1996; Yao et al.,
2000), in some cases progressing to clinical trials (Persson et al.,
1998; Tramont and Johnston, 2003). Overall, however, the
approach has been under-researched, perhaps in part due to a
perceived lack of improvement in nAb induction, compared to
other vaccine approaches (Daniel et al., 1994; Polacino et al.,
1999; Race et al., 1995; Richmond et al., 1998; Verrier et al.,
2000). Underpinning this lack of success are several challenges
that may need to be overcome before VLPs can realize their full
potential as vaccines.
A key technical issue with VLP or other membranous
vaccines is their tendency to elicit “anti-cell” antibodies against
non-Env membrane proteins. These antibodies can have
unpredictable side effects in neutralization assays that vary
from neutralization (Arthur et al., 1992; Chan et al., 1992) to
enhancement (Giannecchini et al., 2001; Verrier et al., 2000).
One possible explanation for these effects is that anti-cell Abs
affect the viability of target cells. Making the situation even
more complex, it has been suggested that enhancing Abs may
even mask the effect of other, neutralizing Abs (Giannecchini et
al., 2001; Hammonds et al., 2005). As a result, it has often been
difficult to unequivocally interpret neutralization data in particle
and cell-based vaccine studies (Buonaguro et al., 2005;
Giannecchini et al., 2001; Hammonds et al., 2005; LaCasse et
al., 1999; Langlois et al., 1992; Poon et al., 2005a, 2005b).
A second challenge for VLP vaccines is that native trimers
may not be the only form of Env present on their surfaces.
Possible non-trimeric forms of Env include gp41 stumps arising
from gp120 shedding (Chertova et al., 2002; McKeating et al.,
1991; Moore et al., 2006), gp120/gp41 monomers (Moore et al.,
2006), and uncleaved gp160 resulting from inefficient proces-
sing. These forms of Env do not resemble functional trimers and
may elicit non-neutralizing antibody responses.
A third potential challenge of particulate vaccines is that
many commonly used adjuvants contain detergent surfactants,
exemplified by Ribi adjuvant, containing Tween 80. Surfactants
stabilize oil-in-water emulsions to enhance the delivery of
proteins to the membranes of immune cells over a large surface
area. However, they may intercalate with or destabilize the lipid
membranes of VLPs, causing Env to be released (Moore et al.,
2006), and as a consequence, trimers may partially or
completely fall apart.
Despite these challenges, VLPs remain among the few
vaccine candidates able to present truly authentic trimers, and
therefore deserve further investigation. In this pilot study, we
evaluated the immunogenicity of VLPs that had been adjusted
to try to overcome some of the abovementioned pitfalls. Env
proteins were truncated to improve expression and to help
ensure proper gp120/gp41 cleavage. A gp120–gp41 disulfide
bond was introduced to prevent gp120 shedding. Furthermore,
Fig. 2. Production of VLPs bearing authentic Env trimers. (A) Secretion of WT
and SOS gp160ΔCT expressed by pCAGGS into transfection supernatant with
or without co-transfection of pNL4-3.Luc.R-E- to induce particle budding, as
indicated. Supernatants were metabolically labeled with 35S and immunopre-
cipitated with mAbs 2G12 and b12 and resolved in reducing and nonreducing
SDS–PAGE, (B) electron microscopy of WT-VLP particles budding from 293T
cells. Nascent particles are indicated by arrows, (C) unlabeled SOS-VLPs were
pelleted from transfection supernatants and analyzed by reducing SDS–PAGE
and Western blot, probing with anti-gp120 mAbs PA1 and B12 or anti-p24
serum, HIVIG or anti-gp120 mAbs B12 and PA1, as indicated, (D) negative
stain electron micrograph of an SOS-VLP particle. Arrows indicate trimers.
Scale bar=50 nM. Inset: model of an Env trimer, reproduced with permission of
Dr. P.D. Kwong (Kwong et al., 2000).
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VLP immune sera, to help identify neutralization amid any
background nonspecific activity.
Results
Production of VLP immunogens
In this pilot study, we opted for moderate Env expression
by plasmid pCAGGS, together with pNL4-3.Luc.R-E- to
express VLPs bearing functional Env trimers (Binley et al.,
2003). To stabilize gp120–gp41 association and eliminate the
potential problem of gp120 shedding that might occur with
“WT-VLPs”, we generated “SOS-VLPs” that introduce a
gp120–gp41 disulfide bond (Abrahamyan et al., 2003; Binley
et al., 2000, 2003), and UNC-VLPs that abolish gp120–gp41
processing (Fig. 1). Collectively, we refer to these as “Env-
VLPs, distinct from “naked” VLPs, lacking Env.
We compared full-length and truncated gp160 forms of
Env on VLPs. Gp160ΔCTWT was completely dependent on
the expression of structural proteins by pNL4-3.Luc.R-E- for
secretion into supernatant (Fig. 2A, lanes 1–3), but full-length
gp160 was secreted into the supernatant, even when pNL4-3.
Luc.R-E- was not co-expressed (not shown), perhaps indicat-
ing spontaneous vesicle formation or an increase in cell lysis.
In addition, gp160ΔCT exhibited higher expression and
gp120/gp41 cleavage than the full-length form, as observed
previously (Binley et al., 2003; Yamshchikov et al., 1995;
Yao et al., 2000). Gp160ΔCTSOS was also fully cleaved and
reducible by DTT (Fig. 2A, lanes 4 and 5). Since gp160ΔCT
is also fusogenic (Abrahamyan et al., 2005; Binley et al.,
2003; Crooks et al., 2005; Edwards et al., 2002), we reasoned
that this is an authentic form of Env suitable for testing as an
immunogen. In contrast to WT- and SOS-VLPs, the Env in
UNC-VLPs was uncleaved, as expected (data not shown and
Moore et al., 2006).
Electron microscopic analysis of 293T cells co-transfected
with pCAGGS gp160ΔCTWT and pNL4-3.Luc.R-E- revealed
efficient particle budding (Fig. 2B). SDS–PAGE and WesternFig. 1. Depiction of various forms of Env on VLP surfaces. (A) WT-VLPs. Env
is proteolytically processed into gp120/gp41 trimers. Gp120 shedding leaves
gp41 stumps behind. Gp120/gp41 monomers are a putative minor species
(Moore et al., 2006), (B) UNC-VLPs. Env is uncleaved, eliminating gp120
shedding. However, Env conformation is inauthentic (Binley et al., 2000),
(C) SOS-VLPs; Env is proteolytically processed and gp120 shedding is
eliminated by a gp120–gp41 disulfide bond (the SOS mutation), while retaining
function. As for WT-VLPs, gp120/gp41 monomers are a putative minor species.blotting of VLP preparations provided further evidence that
gp160ΔCT was associated with particles (Fig. 2C). The Gag
to Env ratio appeared to be similar in WT-, SOS- and UNC-
VLPs and live activated HIV preparations ADA and MN in
Western blots (data not shown). Concentrated VLPs
preparations (1000×) typically contain 5 μg gp120 per ml
(determined by comparison to a known JR-FL gp120
reference in Western blot) and 500 μg total protein per ml,
measured spectrophotometrically. Again, the 1000× concen-
trated live inactivated virus preparations were very similar.
High-resolution negative stain electron microscopy revealed
trimers on the surfaces of WT-VLPs (Fig. 2D), similar to
those observed on inactivated SIV (Zanetti et al., 2006; Zhu
et al., 2003, 2006). The average spike density on several VLP
electron micrographs was 27 (range 15–37), approximately
twice the number previously counted on live inactivated
HIV (range 7–14) (Chertova et al., 2002; Zhu et al., 2003,
2006).
Analysis of Env oligomers
Analysis of Env liberated from WT- and SOS-VLPs in BN-
PAGE revealed a major band of approximately 400 kDa,
248 E.T. Crooks et al. / Virology 366 (2007) 245–262corresponding to authentic trimers (Zanetti et al., 2006; Zhu et
al., 2006), as well as a gp120/gp41 monomer band (Fig. 3A;
Moore et al., 2006). This contrasts with soluble gp140SOS that
readily dissociates into monomers (Schulke et al., 2002),
suggesting that expression in membranes lends some stability to
Env trimers, as we initially hypothesized. The dominance of
trimer band in both WT and SOS-VLPs suggests that gp120
shedding from WT-VLPs is not a major problem (Chertova et
al., 2002; Zhu et al., 2003, 2006). However, probing similar
native PAGE blots with gp41 antibodies reveals gp41 stumps in
WT that are not seen with SOS (Moore et al., 2006), indicating
that some gp120 shedding does occur (data not shown). The
consistent induction of gp41 immunodominant loop antibodies
in natural infection suggests that gp41 stumps are a common
antigen that might be best eliminated from immunogens,
perhaps by the SOS mutation.
In contrast to WT- and SOS-VLPs, UNC-VLP-derived Env
separated as several species that appear to be monomers,
dimers, trimers and tetramers (Fig. 3A) (Earl et al., 1990; Moore
et al., 2006; Staropoli et al., 2000; Zhang et al., 2001).
Denaturing but not reducing conditions caused WT and SOS
trimers to dissociate into monomers (Fig. 3B), but UNC
oligomers remained largely unchanged (Fig. 3B), as they may
be cross-linked by inter-trimer disulfide bonds (Billington et al.,
2007). Denaturing and reducing conditions eliminated oligo-
mers in all preparations (Fig. 3C). SDS–PAGE gels run in
parallel indicated that little, if any uncleaved Env existed in WT-
VLPs (Fig. 3D) and confirmed that reducing conditions
disrupted the gp120–gp41 SOS bond (compare Figs. 3D and
E). Here, the gp120 from WT- and SOS-VLP appeared as a
doublet. We previously proposed that the two forms of gp120
arise from trimers and putative monomers of gp120/gp41
present on virion surfaces (Moore et al., 2006).
Immunogenicity of VLPs in guinea pigs
In this pilot study, we wished to devise an immunization
algorithm suitable for further development. We evaluated
multiple concepts relating to immunogens and the end stageFig. 3. Native PAGE of VLP-derived Env proteins. WT-VLPs, UNC-VLPs and
SOS-VLPs were compared in Bis–Tris gels in (A) native (blue-native), (B)
denaturing but nonreducing and (C) reducing conditions. Ferritin was used as a
molecular weight marker with bands at 439 and 220 kDa, as indicated. The same
samples were analyzed by SDS–PAGE in (D) nonreducing and (E) reducing
conditions.serum analysis. We immunized a total of 17 guinea pigs with
recombinant JR-FL gp120, UNC-VLPs, SOS-VLPs and naked
VLPs. Animals were immunized 3 times at 6 week intervals
with bleeds collected 1 or 2 weeks thereafter (Fig. 4A).
Although VLPs are known to induce potent Ab responses, even
without adjuvants (Lorin et al., 2004; Wagner et al., 1998), to
ensure maximal Ab titers, we included adjuvants in our regimes
(Hammonds et al., 2005). One consideration was that emulsion-
based adjuvants could disrupt membranes. We therefore
selected immunostimulatory DNA CpG as our main adjuvant,
which is unlikely to affect VLP membranes. However, the CpG
formulations used were optimized for rabbits and mice, and it
was not known if they would be effective in guinea pigs, for
which a commercially available CpG product was not available.
Therefore, in a few animals (P1, P13 and P14), CpG was
supplemented with Ribi Ras3c or QS-21, as indicated (Fig. 4).
Binding titers to gp120 and a gp41 peptide
Serum gp120 titers were measured over the course of
immunizations. Of the 3 gp120-immunized control animals,
P1 had the highest titer (Fig. 4A), perhaps owing to the QS21
adjuvant. In the Env-VLP-immunized animals, we observed
high anti-Env titers, comparable to the A62 human plasma
and gp120-immune sera (Fig. 4A). The kinetics of the
responses to Env-VLPs was rapid: high titers were generated
even after a single inoculation (compare animals S2 and S11
in Fig. 4B). The animals that received VLPs formulated in
Ribi or QS21 as well as CpG generated titers similar to
others, suggesting that CpG was sufficient for maximum
titers. As expected, naked VLPs did not elicit significant
gp120 titers (Figs. 4A, B).
To evaluate the conformation dependency of antibody
binding, we measured serum titers against denatured and
reduced gp120 (dgp120). In most Env-VLP sera, dgp120 titers
were b10% of those against intact gp120 (exceptions were S8
and S11), but in gp120-immunized animals, they were even
lower. In contrast, an HIV-1 seropositive donor plasma exhi-
bited similar titers to dgp120 and intact gp120. Taken together,
this suggests that Env conformation was well preserved during
adjuvant formulation and delivery and that Ribi or QS-21
formulation had similar effects on antigens compared to CpG
alone.
To determine the effect of the SOS mutation on gp41
exposure, we measured antibody responses against a peptide
derived from the immunodominant epitope of gp41 (the
“AVERY” peptide). Most Env-VLP sera had very low titers.
Exceptions were animals S7 and S8 that had been immunized
with UNC-VLPs. As anticipated, the naked VLP and gp120
sera did not react with the peptide. In contrast, the HIV-1
seropositive plasma exhibited a high titer, in line with the use of
similar peptides for HIV-1 diagnosis (Fig. 4A).
Mapping the specificity of immune sera
To map serum specificity, we used virus capture competi-
tions and peptide ELISAs.
Fig. 4. Guinea pig serum Ab binding titers against Env. (A) Guinea pigs were immunized with JR-FL gp120, SOS-VLPs, UNC-VLPs, or naked VLPs, formulated in
ImmunEASY CpG and in some cases Ribi or QS21, as indicated. Mature IC50 titers at the end of immunizations against JR-FL gp120 in intact and denatured (dgp120)
forms and the gp41 “AVERY” peptide are shown. Progressively darker cells are used to visually differentiate binding potency. (B) Kinetics of gp120 serum titer
maturation during immunization in animals S2, S11 and P18. Arrows indicate days of immunization.
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To determine the effect of sera on mAb-mediated particle
capture (Derby et al., 2006), graded dilutions of sera were
mixed with WT-VLPs bearing VSV-G, which were then added
to mAb-coated microplates. This assay has the advantage of
employing particulate (and therefore native) Env rather than
gp120 or other soluble forms of Env. Using two different
V3 mAb prototypes, LE311 and 39F, we found that SOS-VLP
and UNC-VLP sera contained high titers of anti-V3 Abs (Figs.
5A, B), as did the HIV+ plasma control. Comparison of these
titers to the IC50s of mAb self-competition allowed an estimate
of the quantity of V3 blocking antibody (Crooks et al., 2005),
which ranges from about 5 to 100 μg/ml in these sera. In
comparison, the gp120 sera showed only moderate titers of V3
competing Abs. As expected, the naked VLP sera did not
exhibit detectable competition.
Focusing next on the CD4 binding site-overlapping mAbs
15e and b12, we found that gp120 serum P1 effectively
inhibited virus capture with a potency corresponding to
approximately 10–60 μg/ml CD4 binding site-overlapping
IgG equivalents. The gp120 serum S1, VLP sera S6, S11and the A62 plasma moderately inhibited capture (Figs. 5A,
B), while most others were weak or completely ineffective.
Inhibition of the two CD4 binding site mAbs by each serum
was largely consistent.
We next examined inhibition by antibodies that bind to the
“CD4-induced” epitope that overlaps the coreceptor binding
site. The A62 HIV+ plasma and most of the Env-VLP sera
effectively blocked X5 capture. Moderate blocking was
observed for sera S6, and P14, and weak blocking was observed
with S1, S2 and the naked VLP sera. The very high titer of the
HIV+ plasma reflects recent findings that these antibodies are
common in natural infection (Decker et al., 2005).
2G12-blocking activity was very low in all guinea pig
sera and the HIV+ plasma control, consistent with the rare
and unusual nature of this specificity. MAb 7B2 was next
used to measure activity to the immunodominant loop of
gp41. The control HIV-1 plasma A62 strongly inhibited
7B2, consistent with the AVERY peptide binding in Fig.
4A. Activity was high in sera S7, S8 and S12, but weak in
most others. For sera S7 and S8, this result is consistent
with reactivity to the immunodominant peptide in Fig. 4A.
Fig. 5. Mapping of guinea pig sera. (A) The ability of guinea pig sera and HIV+ human plasma A62 to inhibit virus capture by various mAbs. Reciprocal IC50
inhibition titers are shown. The IC50 of each mAb to self-inhibit capture is also shown (given in μg/ml). Epitopes are given in parentheses as the V3 loop, CD4 binding
site (CD4bs), CD4-induced epitope (CD4i), the mannose epitope of 2G12 on gp120 (mann.) or the gp41 cluster I region. (B) Representative inhibition curves of LE311
and 15e mAb capture by sera as indicated. (C) Midpoint titers against peptides spanning the V3 loop of JR-FL gp120. Progressively darker cells are used to
differentiate binding potency. n.d.=not done.
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binding only nAbs as SOS and WT trimers (Moore et al.,
2006). 7B2 blocking by the S12 serum is anomalous and
difficult to explain, given that this site is occluded on SOS-
VLPs (Moore et al., 2006). Another guinea pig recently
immunized with WT-VLPs also developed 7B2 blocking
activity, perhaps arising from exposure of gp41 stumps
following gp120 shedding (data not shown).
Peptide ELISA
We next assessed serum binding to a panel of overlapping
peptides spanning the V1, V2 and V3 loops (Fig. 5C). Some
sera had weak activity against the V1 loop, particularly SOS-
VLP sera S12, P13 and P15 (not shown). The V1 loop has, in
fact, emerged as a common specificity in gp120-immune sera(Derby et al., 2006; Garrity et al., 1997; He et al., 2002; Li et al.,
2006). However, none of the sera reacted with the V2 loop (not
shown). The A62 plasma did not react effectively with any of
these peptides.
A major focus of many ENV-VLP sera appeared to be the N-
terminus of the V3 loop, specifically peptides 8838
(TRPNNNTRKSIHI) and 8839 (NNNTRKSIHIGPGRAF)
(Fig. 5C). The A62 plasma and several V3 loop-specific
mAbs, including LE311 and 39F (not shown), also recognized
these peptides. We found that the gp120 sera had relatively low
V3 peptide titers, in line with the weaker V3 mAb capture
inhibition (compare Figs. 5A and C). The reactivity of the Env-
VLP sera to V3 peptides was generally stronger, but quite
variable. Interestingly, V3 mAb competition (Fig. 5A) was not
always associated with V3 peptide reactivity, suggesting that
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approximated by peptides.
Collectively, our mapping efforts indicate that SOS-VLPs
and UNC-VLPs elicit high titers of V3 loop-specific Abs and
often quite high titers of CD4i-overlapping Abs, but weak CD4
binding site-overlapping antibodies. In contrast, gp120 sera
exhibited moderate V3 and CD4i titers and moderate to high
titers of CD4bs-overlapping Abs. It is possible that gp120 and
Env-VLP sera differ in that the gp120 might exist in a native
conformation, while forms of Env presented on the VLPs might
resemble “triggered” forms of Env, in which the V3 loop and
coreceptor binding sites are more exposed, perhaps by virtue of
gp120 association with gp41. The SOS mutation did, however,
appear to largely prevent exposure of the gp41 immunodomi-
nant epitope, as intended. Regarding adjuvants, there was
generally insufficient evidence to suggest that QS21 or Ribi
added much beyond that achieved by CpGs. A possible
exception was that the gp120 response in P1 was stronger and
more focused on the CD4 binding site.
Analysis of neutralization activity
Reports on particle immunogens for HIV-1 have variably
described neutralization or enhancement of infection by
immune sera (Arthur et al., 1992; Buonaguro et al., 2005;
Haffar et al., 1991; Hammonds et al., 2005; McBurney et al.,
2007; Poon et al., 2005a, 2005b; Verrier et al., 2000). This
may be in part related to the generation of antibodies against
non-Env membrane proteins that can have unpredictable
effects on infection. Indeed, it is often unclear whether
“neutralization” is mediated by Abs directed to Env or to
other membrane proteins (“anti-cell” antibodies). With this in
mind, we evaluated neutralization in several formats,
incorporating controls to help distinguish anti-Env activity
from nonspecific effects.
We first measured neutralization against the index primary
virus, JR-FL, in a luciferase assay using canine CF2 target cells
(Fig. 6A). Canine CF2 cell targets were selected in an attempt to
minimize the effects of anti-cell antibodies generated against the
293T (human) produced VLPs. Some SOS- and UNC-VLP sera
(S6, S11, S12, P14 and P15) enhanced infection by 2–3 fold
(Fig. 6A, column 1), even at high dilutions (exemplified by
serum P15 in Fig. 7A), while other Env-VLP sera and the gp120
sera had no effect. In contrast, the naked VLP sera exhibited
apparent “neutralization”. In the following two sections, we
separately address the activity of gp120/Env-VLP sera and
naked VLP sera in the CF2 neutralization assay.
Neutralization activity of the gp120 and Env-VLP sera
Enhancement could arise either from antibodies directed to
Env that somehow activate fusion or from antibodies directed to
membrane components that facilitate virus attachment. To
investigate, we tested the effect of sera on SIVmac316 infection
(Fig. 6A, column 2). This virus was made by transfection of the
same 293Tcells as the HIV pseudoviruses and, therefore, would
be expected to bear the same set of cellular membrane proteins.Similar enhancement of this virus was noted with many of the
sera, as it was for JR-FL, suggesting that the enhancement
stemmed from Abs directed to non-Env membrane components
of VLPs. In contrast, the control HIV+ plasmas A62 and N308
neutralized JR-FL, but not SIVmac316.
It has been suggested that enhancing Abs may mask
neutralization (Giannecchini et al., 2001; Langlois et al., 1992).
Indeed, in a previous study, removal of anti-cell antibodies
against FIV particle vaccine by adsorption against producer cells
was reported to uncover neutralizing activity (Giannecchini et al.,
2001). To test this concept, we adsorbed SOS-VLP serum P15
against 293T cells and removed∼90% of the anti-cell reactivity,
as assessed by FACS (data not shown), while retaining strong
gp120 titers (diluted only 2–3 fold during adsorption). However,
this did not uncover any neutralization (not shown).
To further determine whether enhancing Abs mask neutraliza-
tion, we spiked the JR-FL-enhancing serum P15with neutralizing
mAb b12. Comparing neutralization by b12 alone to a b12/serum
mixture (Fig. 7B) showed that the serum did not reverse b12
neutralization. Thus, infection by a virus that has been neutralized
was not rescued by factors that otherwise enhance infection. In
further neutralization assays using a VSV-G pseudotyped virus,
the Env-VLP sera showed no enhancement (Fig. 6A, column 3),
perhaps because VSV-G entry is amphotropic and therefore
influenced by different factors compared to HIV and SIV.
Though we did not see convincing neutralization against the
index virus, JR-FL, ELISAs had suggested that sera contained
potent anti-Env reactivity (Fig. 4). To assess neutralization in
alternative conditions, we measured “post-CD4” activity
(Crooks et al., 2005) by pre-incubating JR-FL particles with
sCD4 and graded dilutions of sera and then measuring infection
of CF2 cells expressing only CCR5. We found that all Env-VLP
and gp120 sera neutralized effectively in this format (Fig. 6A,
column 4), as did both HIV+ plasmas. However, as expected,
naked VLP sera did not. Enhancement was not observed in the
post-CD4 format, providing further evidence that enhancing
effects are negated when the virus is neutralized. With reference
to our previous analysis (Crooks et al., 2005), post-CD4
neutralization suggested the presence of Abs that recognize the
V3 loop and/or CD4-induced epitope(s), consistent with our
mapping data (Fig. 5). The contribution of V3 Abs to
neutralization was investigated in “peptide interference”
neutralization assays (Beddows et al., 2005; Li et al., 2006;
Selvarajah et al., 2005). Here, V3 peptides strongly inhibited
post-CD4 neutralization by serum P13 (Fig. 7C), suggesting a
major role for V3 Abs in post-CD4 neutralization.
Although we were encouraged by the strong serum activity
in the post-CD4 format, it is important to point out that this
assay dramatically expands access to epitopes that are normally
cryptic in native trimers and become exposed only fleetingly
during infection, as evidenced by the generally weak to modest
activity of these types of antibodies in traditional neutralization
assays (Bou-Habib et al., 1994; Crooks et al., 2005; Decker et
al., 2005). Indeed, most HIV+ plasmas contain high concentra-
tions of CD4i Abs without having strong neutralizing titers.
Therefore, the significance of post-CD4 activity should not be
over-interpreted.
Fig. 6. Serum neutralizing activity in various assays. The neutralization activity of guinea pig sera and HIV+ plasmas A62 and N308 was measured using (A) CF2 cells
or (B) TZM-BL cells (columns 1–5) or PBMCs (columns 6 and 7) as targets. In the CF2 assay, JR-FL, SIVmac316, HXB2 and SF162 308T/H Envs were gp160ΔCT
and the 1196 Env was a full-length gp160. The virus producer cells (293T cells or human PBMC, hPBMC) and the target cells in which neutralization was measured
are indicated. *Denotes enhancement in the presence of serum. # Indicates “neutralization” that is likely to be the result of toxicity against the target cells or other
nonspecific factors. Progressively darker cells are used to differentiate binding potency. n.d.=not done.
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virus in the standard format, we tested some more sensitive
isolates. The P1 serum strongly neutralized HXB2, a highly
sensitive X4 isolate (Fig. 6A, column 5). Perhaps underlying
this activity, mapping had indicated high levels of CD4bs-
overlapping Abs in this serum (Fig. 5A). However, no Env-VLP
other serum neutralized HXB2, probably because the predomi-
nant V3 Abs (Fig. 5) do not cross-react with this isolate.
The gp120 serum P1 weakly neutralized SF162, as did SOS-
VLP sera S12 and P15, but no others (not shown). We also
observed weak neutralization against ADA and BaL (not
shown), but moderate neutralization against the 1196 isolate
(Fig. 6A, column 6, and Fig. 7D). Epitope interference assays
suggested that the 1196 neutralization was V3-mediated (Fig.
7E), consistent with the greater susceptibility of this virus to V3-
directed neutralization (Binley et al., 2004).Collectively, our neutralization data so far suggested that
Env-VLP sera neutralize via anti-V3 Abs and the gp120 serum
P1 neutralizes via CD4 binding site-overlapping Abs. The lack
of SF162 neutralization via the Env-VLP sera may stem from
differences in the V3 loop between JR-FL and SF162. When we
substituted a residue in SF162 to match the N-terminus of the
V3 to JR-FL, the mutant virus was significantly more sensitive
to Env-VLP sera (Fig. 6A, column 7). The SF162 variant was
slightly less sensitive to the neutralizing N308 HIV+ plasma,
revealing that the mutation did not globally increase neutraliza-
tion sensitivity.
Analysis of neutralization by naked VLP sera
In light of the absence of JR-FL neutralization by gp120 and
Env-VLP sera, it was not immediately clear why naked VLP
Fig. 8. Analysis of nonspecific neutralization in naked VLP sera. (A) The
nonspecific neutralizing effect of P18 on 1196 infection, compared to a control
with no serum. (B) The effect of P18 on b12 mAb neutralization of JR-FL. In the
spiking experiment, P18 at a final dilution of 1:4 was mixed with 2.5 μg/ml b12
and the mixture was serially diluted and added to the virus. (C) Reactivity of
guinea pig serum P12 with 293T, U87 and CF2 cell lines measured by FACS.
The pre-bleeds were used at a 1:50 dilution and final bleed was used at a dilution
of 1:250.
Fig. 7. The nature of Env-VLP sera neutralization and enhancement. (A) SOS-
VLP serum P15 enhancement of JR-FL virus infection in the CF2 assay. (B) The
effect of spiking P15 serum with the neutralizing mAb b12 compared to
b12 mAb alone on JR-FL infection. Here, the P15 serum starting dilution was
1:4 and the b12 starting concentration was 2.5 μg/ml in both samples. The P15
serum and b12 mAb were diluted in parallel. (C) Post-CD4 activity of P13
against JR-FL, with and without interference by fixed 20 μg/ml concentrations
of V3 peptides, TRPNNNTRKSIHIGP (8837) and NNTRKSIHIGPGRAF
(8838). (D) Representative neutralization curves against virus 1196 in the CF2
assay. (E) Neutralization by the P14 serum against 1196 in the presence or
absence of interfering V3 peptides 8837 and 8838, as above. The effect of the
peptides alone on infection was negligible (not shown).
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the neutralization was nonspecific came from the observation
that the sera also neutralized SIVmac316 (Fig. 6A, column 2).
In addition, interference of P18 neutralization of the 1196
isolate using V3 peptides had no effect (not shown), consistent
with nonspecific neutralization.
Another method to help distinguish nonspecific activity from
genuine neutralization is that the former may not embody the
sigmoidal dose–response typical of neutralization. We and
others have observed that IC90 titers typically occur at
approximately a 10 fold higher Ab concentration than the
IC50 (Binley et al., 2004). In contrast, the “neutralization”naked VLP sera took the form of “shallow” curves, with IC50
titers of ∼1:500 in many cases, that never reached an IC90 (at a
dilution of 1:20 or greater), suggesting nonspecific neutraliza-
tion (Fig. 8A). Different isolates were affected to varying
degrees by these nonspecific antibodies (Fig. 6A, column 5) in a
way we do not yet understand.
To determine whether nonspecific neutralization influences
genuine neutralization, we evaluated the effect of spiking
a naked VLP serum (P18) with the b12 mAb at 2.5 μg/ml.
Here, b12 neutralization could be distinguished only when
its concentration was sufficient to reach an IC90 (compare
Figs. 8A, B).
One possible explanation as to why naked VLP sera
nonspecifically neutralized while Env-VLP sera generally
enhanced might be that the specificity or titer of anti-cell Abs
in Env-VLP sera may differ from those in naked VLP sera.
FACS analysis revealed that naked VLP serum P18 bound more
potently to 293T cells than serum P12 (median fluorescence
intensities at a 1:2000 serum dilution were 717 and 181,
respectively). These differences could underlie the differential
effects of these sera in neutralization assays, where nonspecific
neutralization might occur above a threshold of anti-cell Abs.
It is possible that the cells in which virus was produced and/
or the target cells in which virus infection is measured might
influence neutralization. We therefore assessed serum binding
to various cell lines by FACS. We found that SOS-VLP serum
P12 reacted extremely strongly with 293T cells, the same cell
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against U87 cells (a human glioma cell line). However, its
reactivity against canine CF2 cells used in the neutralization
assays described above was much lower, though still sig-
nificantly positive. This suggests that a fraction of the anti-cell
activity in sera is cell line-specific.
Alternative neutralization assays
To investigate the effect of differential cell reactivity on
neutralization measurement, alternative neutralization assays
were performed at a separate site (D.C.M.). In an assay
measuring infection of 293T cell-produced virus in TZM-BL
target cells (Fig. 6B columns 1–5), the nonspecific neutralizing
activity of naked VLP sera was much lower and reactivity
against the MuLV control virus was also low (Fig. 6B, column
5). Serum titers against SF162, JR-FL, 1196 or BaL
pseudotyped viruses were, in general, higher (Fig. 6B, columns
1–4) than the corresponding titers using CF2 target cells (Fig.
6A and data not shown). Serum P1 was very potent against
SF162 (Fig. 6B, column 1), consistent with the presence of
CD4 binding site-overlapping antibodies. Neutralizing activity
against JR-FL, though higher than before, remained relatively
modest (Fig. 6B, column 2). Neutralization of 1196 and BaL
was more impressive. Titers against 1196 were, in many cases,
more than ten fold higher than in the initial CF2 assay
(compare Fig. 6A, column 6 to Fig. 6B, column 3). It is
possible that Ribi and QS21 adjuvants given to animals P13
and P14 contributed to especially high titers.
The above results were surprising, considering the greater
overall anti-cell reactivity that would be expected against the
human HeLa-based TZM-BL target cells. In addition to the cell
line, differences in protocol may contribute to this effect. In the
TZM-BL assay, but not the CF2 assay, sera, virus and cells are
co-incubated during the entire infection period. We have found
that this tends to increase neutralization IC50 titers (not shown).
Another possibility may relate to coreceptor density. The CF2
cells in the initial assay express high levels of CCR5 to assist in
efficient infection. This may decrease the window of opportu-
nity for antibodies that neutralize via binding the V3 or
coreceptor binding sites (Crooks et al., 2005). The lower CCR5
density on TZM-BL cells could therefore contribute to the
greater neutralization potencies. Finally, in the CF2 assay, we
used a short spinoculation step to increase overall infection
levels that was not used in the second assay. However, we found
that spinoculation does not significantly affect the activity of
neutralizing mAbs (not shown).
In further neutralization assays employing PBMC-produced
JR-FL primary viruses, also assayed on PBMC, we observed
complete neutralization with most VLP sera at a 1:18 dilution,
but little or no neutralization by the gp120 sera (Fig. 6B, column
6). We also observed strong activity against SIVmac251 in this
format (Fig. 6B, column 7). It appears that, as in the CF2 assay,
toxicity adversely affected neutralization measurement. Taken
together, these results highlight the unpredictable effects of anti-
cell antibodies. Given that the rules governing these effects are
far from clear, our results provide a cautionary note, suggestingthat particular care should be taken when examining sera
generated against membranous antigens.
Measurement of trimer binding in blue native PAGE
In circumstances when neutralization assays are compro-
mised by high background activity, BN-PAGE offers an
independent way examine trimer binding. We recently reported
that a shift in mobility of a VLP-derived trimer band in BN-
PAGE, associated with a depletion of unliganded trimer,
correlates with mAb neutralization (Crooks et al., 2005;
Moore et al., 2006). Here, we adapted the method to measure
neutralization by polyclonal sera and plasmas. We first tested
the ability of the guinea pig sera to bind to JR-FL Env trimers in
the presence or absence of additional neutralizing mAb b12
(Fig. 9A). We found that Env-VLP sera depleted the unliganded
trimer to 43–96% of the control density, suggesting weak
neutralization. Tellingly, the naked VLP serum P16 did not
deplete unliganded trimers significantly, suggesting that non-
specific effects are inconsequential to this assay. In experiments
in which VLP sera and b12 were mixed together, the effect of
b12 to deplete unliganded trimers was not affected (Fig. 9A).
The shifted trimers were somewhat diffuse compared to when
b12 was used alone, perhaps indicating multiple forms of
trimer–Ab complexes.
For reference purposes, we analyzed the ability of the
neutralizing human HIV+ plasma N308 and the non-neutraliz-
ing plasma L503 to shift JR-FL trimers. Like b12, N308
potently depleted unliganded trimers (Fig. 9B). At low dilution,
this was accompanied by a smear that resolved into distinct
shifted bands at higher dilutions, suggesting differing numbers
of neutralizing Abs attached to trimers. In contrast, the non-
neutralizing plasma L503 did not detectably deplete unliganded
trimers, even at the lowest dilution, confirming that neutraliza-
tion can be measured unequivocally by BN-PAGE, as defined
by a loss of unliganded trimer, accompanied by a gain in higher
molecular weight liganded forms.
We next determined whether Env-VLP sera could mediate
more effective trimer shifts of isolates they effectively
neutralized. In Fig. 9C, mAb b12 and the Env-VLP sera P13,
P14 and S12 all shifted SF162 308T/H trimers to varying
degrees. P13 was more effective than P14 and S12, as reflected
in neutralization assays (Fig. 6A, column 7). On the other hand,
the naked VLP serum P16 did not shift trimers, consistent with
its lack of neutralization.
Strong reactivity of VLP sera and HIV plasmas to a non-Env
component of VLPs
We next examined the reactivity of various antibodies with
VLPs. Thus, we compared neutralizing mAbs, VLP sera, HIV
patient sera and HIV negative sera as Western blot probes for
VLPs in native PAGE with some remarkable results (Fig. 9D).
The neutralizing mAb cocktail bound both the strong trimer
band, and the weaker monomer band (Moore et al., 2006). In
contrast, the SOS-VLP serum bound extremely strongly to a
∼150 kDa band and much less to the trimer, suggesting that
Fig. 9. Blue-native PAGE trimer shifts distinguish neutralization from nonspecific effects. (A) JR-FL 140T SOS-VLPs were incubated with VLP sera and/or mAb b12
Fab, as indicated, at a final dilution of 1:3 for sera and 20 μg/ml for mAb b12. Samples were resolved by BN-PAGE and Env proteins were visualized by Western blot.
The bands are identified in cartoon form as unliganded and liganded trimers. In liganded complexes, for clarity, the antibodies are depicted as Fabs. The density of the
unliganded trimer band relative to that in the untreated VLP control (taken as 100%) is given in the bar below the gel. (B) SOS-VLP trimer shift assays were performed
with graded dilutions of the neutralizing N308 or non-neutralizing L503 plasmas at the dilutions indicated. (C) Trimer shifts using sera at a 1:2 dilution were performed
using the neutralization-sensitive isolate SF162 308T/H. MAb b12 IgG was used at 30 μg/ml. (D) SOS-VLPs or SIVmac316 VLPs were probed with a gp120 mAb
cocktail (Crooks et al., 2005; Moore et al., 2006), VLP sera (P15 or P18), HIV-infected plasma (N308) or HIV negative plasma.
255E.T. Crooks et al. / Virology 366 (2007) 245–262gp120/gp41 monomers are a prime target of B cells. However,
surprisingly, the naked VLP serum also bound extremely well to
a band of the same size as the monomer. Since the naked VLP
sera do not react with Env (Fig. 4), this indicates reactivity to a
non-Env component of VLPs. An HIV positive patient serum
gave similar results to the SOS-VLP sera: weak trimer binding,
but strong reactivity to a band around the size of the monomer.
In contrast, an HIV negative serum was essentially unreactive.
Probing SIV-VLPs, we again observed strong binding of HIV+
plasma to the∼150 kDa protein, suggesting that VLPs and HIV
infection elicits strong responses to a non-Env protein (Gag or
host protein) component of VLPs. Overall, these results
suggests that non-trimer components of particles are preferred
targets for B cells both in immunizations and natural infection.
Discussion
Here we showed that VLPs are a versatile vaccine platform,
providing a complete framework to assess VLP-Env trimers as
immunogens and a powerful end-stage system for analyzing
sera (Crooks et al., 2005; Derby et al., 2006). Our initial vaccine
approach emerged from the idea that earlier particulate HIV
vaccine candidates may have failed to elicit broadly neutralizing
antibodies because the Env trimers are unstable. In particular,
gp120 shedding might leave behind depleted trimers or gp41
stumps (Chertova et al., 2002; Grovit-Ferbas et al., 2000;
Hammonds et al., 2003; McKeating et al., 1991; Moore et al.,
2006). To address this problem, we introduced a disulfide
bridge to stabilize gp120–gp41 (SOS). To further optimize VLPimmunogens, we truncated the gp41 cytoplasmic tail to increase
expression and gp120/gp41 cleavage, with only a mild effect on
neutralization sensitivity (Abrahamyan et al., 2005; Binley et
al., 2003; Edwards et al., 2002; Gabuzda et al., 1992;
Mammano et al., 1997). Since SOS-VLPs retain fusion
competency (Abrahamyan et al., 2003; Binley et al., 2003;
Crooks et al., 2005; Moore et al., 2006), we reasoned that they
were a viable starting point for testing the ability of authentic
trimers to elicit neutralizing antibodies (Abrahamyan et al.,
2003; Binley et al., 2003).
Nonfunctional gp120/gp41 monomers may be a prime Ab
target on VLPs
In spite of very high binding titers to monomeric gp120 and
neutralization activity against sensitive primary isolates, SOS-
VLP sera did not potently neutralize the JR-FL parent virus or
most other neutralization-refractive isolates. This mirrors the
majority of vaccine studies in which immune sera neutralize
only V3-sensitive primary isolates like BaL, SF162 and 1196
(Koff et al., 2007). Indeed, the neutralizing activity of VLP sera
appeared to stem at least in part from V3 antibodies. The fact
that the V3 loop is cryptic on trimers of neutralization-resistant
viruses like JR-FL (Bou-Habib et al., 1994) raises the question:
where do these anti-V3 Abs come from? Since our control
immunogens, UNC-VLPs also elicited strong responses to the
V3 loop, we suggest that, in each case, B cells responded to
forms of Env other than functional trimers, perhaps gp120/gp41
monomers (SOS-VLPs) or unprocessed gp120–gp41 (UNC-
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the SOS mutation is only a partial solution toward presenting
trimeric Env on VLPs for vaccine purposes.
Previous analyses have suggested that gp120/gp41 mono-
mers, unlike trimers, these are highly accessible to V3 Abs
(Burrer et al., 2005; Moore et al., 2006; Nyambi et al., 1998;
Poignard et al., 2003) andmay be a primary target for B cells.We
hypothesize that monomers act as decoys, distracting the
attention of B cells from the more compact trimers, in what
might be considered an “immunogenic hierarchy”. Evidence of
such hierarchies in studies of immune responses to HIV-1 has in
fact been widely reported (Cleveland et al., 2000; Garrity et al.,
1997; Jelonek et al., 1996; Liu et al., 2006). Perhaps at odds with
this concept, affinity selection in germinal centers dictates that
higher affinity B cell blasts proliferate at the expense of lower
affinity ones. Thus, antibody responses to multiple separate
proteins might be expected to develop independently and
equivalently, as if they were given alone, as for the trivalent
measles, mumps and rubella vaccine (Usonis et al., 2005).
However, the situation with VLPs is in fact quite different
because trimers and monomers are linked on the same particle
and therefore may be considered as a single target. Thus, B cells
would be selected against only the most accessible foreign target
(s), the V3 loop, of the most accessible structure (the monomer),
at the expense of other epitopes, in this case, the trimer.
We previously showed that monomer is only a minor
component of particles, compared to the predominant trimer
(Fig. 3 and Moore et al., 2006). This raises the question why a
minor species would dominate the B cell response. The answer
may simply be that form rather than quantity dictates the
antibody response. We previously showed that non-neutraliz-
ing antibodies capture HIV with high efficiency, even though
they do not bind efficiently to trimers, suggesting that
monomer binding mediates the capture. BN-PAGE further
confirmed the more promiscuous binding properties of
monomers (Moore et al., 2006), suggesting that the monomer
may dominate as an antigen simply because it is a particularly
accessible target.
Of particular significance to the present study, a previous
report compared the immunogenicity of UNC and “SOSIP”
mutants of a soluble gp140 glycoprotein and gp120 monomer in
rabbits (Beddows et al., 2007). Sera generated against SOSIP
stabilized trimers potently neutralized the parental JR-FL isolate.
This activity was not due to V3 Abs, but its precise specificity
remains unclear. Although the neutralization was type-specific,
because the JR-FL isolate is refractive to neutralization, these
results suggest the SOSIP may be a possible step in the right
direction for HIV vaccine research.
Both SOSIP gp140 and SOS-VLPs vaccine approaches
emerged from the early observation that SOS gp140 readily
dissociates into monomers and the consequent need to
stabilize them as trimers (Schulke et al., 2002). The relative
success of SOSIP gp140 raises questions about what might
underlie the quite different findings of the present study. At
odds with the idea that particles present native Env, and
therefore may be particularly effective immunogens, the
results of these two studies might be interpreted to suggestthat the reverse is, in fact, true. More likely, however, the
differences probably arise from the fact that monomeric forms
of Env were completely eliminated in SOSIP gp140
immunizations, but not in SOS-VLPs (Moore et al., 2006).
However, since VLP trimers are recognized exclusively by
neutralizing Abs (Moore et al., 2006), unlike even the most
advanced soluble trimers (Dey et al., 2006), VLPs may still
have an advantage for presenting truly native trimers, if the
right formulation can be found.
Factors affecting the quality of the immune response
We were cautious that commonly used adjuvants such as
alum and Ribi might disrupt particle membranes, perhaps
affecting Env conformation. Therefore, we selected immunos-
timulatory CpG as our primary adjuvant. Our mapping data
indicate, however, that sera from the few animals that received
VLPs in emulsion adjuvants differed little from those who
received CpG alone. There was an indication, however, that the
additional adjuvants led to higher neutralization titers against
certain viruses (exemplified by the activities of sera P13 and P14
in Fig. 6). Therefore, it will be worth investigating further how
adjuvants can help in getting the most out of these immunogens.
The route of immunization could affect the stability of VLPs
after immunization, perhaps also affecting the quality of the
antibody response. Intranasal administration, for example, has
been shown to be effective (McBurney et al., 2007). However,
since the nAb titers in other studies do not appear to dramatically
better, the more fundamental problem of nonfunctional forms of
Env may need to be solved before the extent of the advantages
offered by varying route and adjuvant can be fully appreciated.
Another, perhaps more significant factor is the choice of model
species for vaccination trials. It has been suggested that some
species may simply not have the IgG repertoire to generate nAbs
(Koff et al., 2007). In line with this idea, we have recently begun
VLP immunizations in macaques that suggest a greater focus on
the CD4bs and improved neutralization activity.
The effects of “anti-cell” antibodies
A drawback of membranous immunogens is that they induce
Abs against non-Env components, exemplified by the strong
reactivity of VLP and HIV patient sera to a non-Env VLP band
in BN-PAGE (Fig. 9D). Antibodies against non-Env VLP
surface components can enhance or nonspecifically “neutralize”
infection in a largely unpredictable manner (Arthur et al., 1992).
The cleanest method to assess neutralization was the native
trimer shift assay (Figs. 9A–C). This assay should in future help
in assessing the progress of any membranous HIV vaccine. On
the other hand, in traditional neutralization assays, we were able
to incorporate controls at various levels to identify and eliminate
any nonspecific activity.
The future of HIV-VLP immunogens
In natural infection, the delay in development of nAbs
(Deeks et al., 2006), despite the early development of gp120
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provide the virus with a valuable fitness advantage by diverting
antibody responses from functional targets. To make progress,
we may need to get beyond these defenses (Burton and Parren,
2000). It may be possible to refocus Ab responses against
trimers (Moore et al., 2006) by modifying or blocking epitopes
on nonfunctional Env (Cole et al., 2004; Garrity et al., 1997;
Keller and Arora, 1999; Selvarajah et al., 2005; Srivastava et al.,
2003). However, it could be argued that trimers are inherently
poor immunogens and that removal of irrelevant forms of Env
may not change that fact. On the other hand, the development of
cross-neutralizing activity in a subset of infected HIV patient
sera, suggests that B cells can in fact eventually respond to
trimers. The neutralizing activity of SOSIP gp140 sera provides
evidence that trimers are not inherently poor antigens. Thus, if
we can find a way to steer B cells away from irrelevant targets,
we may in future be able to entice responses against native
trimers.
Materials and methods
Plasmids and mutagenesis
The plasmid pCAGGS was used to express membrane-
bound forms of the primary R5 isolate, JR-FL (Binley et al.,
2003; Moore et al., 2006). We expressed full-length gp160 and
gp160ΔCT, truncated at amino acid 709, leaving 3 amino
acids of the gp41 cytoplasmic tail. The SOS and UNC mutants
to stabilize gp120–gp41 association have been described
previously (Binley et al., 2000). Gp160-expressing plasmids of
isolates SF162, BaL, HXB2, ADA and 1196 were obtained
from Drs. Leo Stamatatos, David Montefiori and the NIH
AIDS Repository. A mutant of SF162 Env in which the
threonine residue at 308 of the V3 loop was exchanged for
histidine (SF162 308T/H) was created by Quikchange
mutagenesis. Truncated gp160ΔCT versions of 1196, SF162,
SF162 308T/H and SIVmac316 Envs were cloned into
pCAGGS in a similar manner to that described for JR-FL
(Binley et al., 2003). The plasmid pVSV-G was obtained from
Dr. Nathaniel Landau. Sub-genomic plasmids pNL4-3.Luc.R-
E- and pSG3ΔEnv have been described previously (Binley et
al., 2002; Li et al., 2005).
MAbs, soluble CD4, recombinant gp120 and HIV+ donor
plasmas
Anti-gp120 monoclonal antibodies (mAbs) included b12 and
15e, directed to epitopes that overlap the CD4 binding site
(CD4bs) (Burton et al., 1994); 2G12, directed to a unique
glycan-dependent epitope on gp120 (Sanders et al., 2002a;
Scanlan et al., 2002); X5 directed to a CD4-inducible (CD4i)
epitope (Labrijn et al., 2003); LE311, 39F and PA1 directed to
the V3 loop (Crooks et al., 2005; Schulke et al., 2002); and B12,
directed to an epitope in the C2 domain of gp120 that is
preferentially exposed on denatured forms of the molecule
(Moore et al., 2006). Anti-gp41 mAb 7B2 is directed to the
cluster I region (Binley et al., 2000).MAb 2G12 was provided by Dr. H. Katinger (Polymun
Scientific Inc., Vienna, Austria). MAbs 39F, LE311 and 7B2
were provided by J. Robinson (Tulane University). MAb B12
was provided by Dr. George Lewis (Institute of Human
Virology, Baltimore, MD). MAb PA1, four-domain soluble
CD4 (sCD4) and JR-FL gp120 were provided by Progenics
Pharmaceuticals Inc (Tarrytown, NY). MAbs b12 and 2G12 are
broadly neutralizing (Binley et al., 2004); mAb X5 neutralizes
primary isolates in the presence of soluble CD4 (Crooks et al.,
2005; Moulard et al., 2002); the V3 loop-specific Abs neutralize
a subset of primary isolates (Binley et al., 2004); mAb 7B2 is
non-neutralizing. The HIV-1-infected donor plasmas A62, L503
and N308 were described previously (Crooks et al., 2005). The
anti-p24 serum was obtained from the NIH AIDS Reagent
Program.
Peptides
Eleven residue-overlapping 15-mer peptides of the V3 loop
of JR-FL were obtained from the NIH AIDS Reagent Program.
Five residue-overlapping 15-mer peptides of the V1/V2 loop of
JR-FL were synthesized at The Torrey Pines Institute for
Molecular Studies and purified to N90%. A peptide of the gp41
immunodominant region, sequence RVLAVERYLKDQQLL-
GIWGCSGKLIC, termed the “AVERY” peptide was purchased
from AnaSpec (San Jose, CA).
Production of VLPs
VLPs were produced by transient transfection of 293T cells
with plasmids pNL4-3.Luc.R-E- and a pCAGGS-based Env-
expressing plasmid by calcium phosphate precipitation. Two
days later, supernatants were collected, precleared by low speed
centrifugation, filtered through a 0.45 μM filter and pelleted at
50,000×g in a Sorvall SS34 rotor. To remove residual medium,
pellets were diluted with 1 ml of PBS then recentrifuged in a
microfuge at 15,000 rpm. VLPs were then resuspended in PBS
at 1000× the original concentration. Particles were inactivated
using aldrithiol (AT-2) (Rossio et al., 1998), after which they
were re-centrifuged and washed with PBS.
Immunoprecipitation
Supernatants of 293T cells were metabolically labeled and
analyzed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS–PAGE), as previously described (Binley
et al., 2000). Reduced and nonreduced samples were prepared
by boiling for 5 min in Laemmli sample buffer (62.5 mM Tris–
HCl, pH 6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue)
in the presence or absence of 20 mM dithiothreitol (DTT).
SDS–PAGE, native PAGE and Western blot
VLP preparations were separated by SDS–PAGE, and
Western blots were probed with mAbs PA1 and B12 diluted to
1 μg/ml in PBS containing 2% nonfat milk, detected with a goat
anti-mouse alkaline phosphatase conjugate (Jackson) and
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Aldrich). VLP-derived Env was also analyzed by blue native
PAGE (BN-PAGE), as described previously (Moore et al.,
2006).
Electron microscopy
Transfected 293T cells producing VLPs were fixed in 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.3) for
2 h. Samples were then washed in 0.1 M sodium cacodylate,
fixed in 1% osmium tetroxide and incubated in 0.5% tannic acid
in 0.05 M cacodylate for 30 min. Following a 10 min wash with
1% sodium sulfate/0.1 M cacodylate buffer and further rinsing
in 0.1 M cacodylate, the cells were dehydrated in a graded
ethanol series, cleared in propylene oxide and embedded in
EMbed-812/Araldite (Electron Microscopy Sciences, Fort
Washington PA). Ultra thin sections were cut and mounted on
parlodion-coated copper grids and stained with uranyl acetate
and lead citrate. The sections were then examined on a Philips
CM-100 electron microscope (FEI, Hillsborough, OR) and
documented on Kodak SO-163 photographic film.
In high magnification negative stain electron microscopy,
aliquots (25 μl) of virus particle preparations were washed in
140 μl of PBS and pelleted by an Airfuge centrifuge (Beckman
Coulter) at 100,000×g for 15 min. The virus particles were then
resuspended and fixed for 30 min in 20 μl of 2.5%
glutaraldehyde/PBS at 4 °C. The fixed virus particles were
washed in PBS and pelleted in Airfuge centrifuge again and
finally resuspended in 15 μl of saline. 4.5 μl of resuspended
sample was placed on a carbon-covered grid for 30 s. Excess
virus particles and buffer were removed by filter paper blotting,
and 5 μl of 1% uranyl formate stain was immediately added and
incubated for 1 min. Excess stain was then removed, and the
samples were allowed to air dry. Sample grids were screened at
×30,000, and electron micrographs were recorded at a nominal
magnification of ×100,000 at 100 kVon a JEOL JEM 1200EX
electron microscope.
Immunogenicity of VLPs in guinea pigs
Dunkin Hartley guinea pigs were immunized with SOS-
VLPs, UNC-VLPs, “naked” VLPs or gp120, at the Scripps
animal facility or Pocono Rabbit Farm (denoted by the animal
identifier prefixes “S” and “P”). Five microgram Env
equivalents of VLPs were used for each dose, as determined
by Western blot, comparing to the known monomeric JR-FL
gp120 standard. Naked VLPs were normalized for equivalent
p24 to the other VLP preparations inWestern blot. Recombinant
monomeric gp120 was initially used at 5 μg dose (immuniza-
tions 1 and 2) consistent with the dose of Env in Env-VLP
vaccinations. However, due to weak responses, the third and
final dose was increased to 50 μg. Most immunogens were
formulated in an equal mixture with the CpG-based adjuvant
ImmunEASY (Qiagen) optimized for rabbits and mice. In some
immunizations, the saponin-based QS21 or Ribi Ras3c
adjuvants were used. All immunizations were administered by
a combination intradermal and intramuscular routes in twolocations each, at days 0, 43 and 97. Sera were collected 1 or
2 weeks after each immunization.
Neutralization assays
Sera were heat-inactivated at 56 °C for 30 min then analyzed
for neutralization. Each assay was performed in duplicate and
repeated at least 2 times. Representative data are shown. HIV+
plasmas A62 and N308 were used as reference controls.
Neutralization assays were performed using either Env-
pseudotyped viruses produced by transfection of 293T cells or
PBMC-grown viruses.
Neutralization assays using CF2 cell targets
Neutralization assays using CF2 cells were described
previously (Crooks et al., 2005; Kolchinsky et al., 2001). Briefly,
virus was incubated with graded dilutions of Ab for 1 h at 37 °C.
The mixture was then added to CF2 cells, spinoculated then
incubated for 2 h at 37 °C, after which the medium was changed.
The cells were cultured a further 3 days and then luciferase
activity was measured. Post-CD4 binding neutralization was
assayed by treating VLPs with sCD4 and graded dilutions of sera
and using CF2 cells bearing only CCR5 as targets (Crooks et al.,
2005). In “peptide interference” neutralization experiments,
fixed concentrations of V3 peptides were added to virus–Ab
mixture to adsorb V3-specific nAbs.
Neutralization assays using TZM-BL cell targets
A neutralization assay using TZM-BL cells has been
described previously (Li et al., 2005), in which trypsinized
TZM-BL cells were added to virus–serum mixtures and left for
3 days without a change of medium or a “wash out” format in
which virus–Ab mixtures were added to wells that had been
pre-seeded with TZM-BL cells, and the medium changed after a
2 h incubation, followed by 2 days of culture.
Neutralization assays using PBMC targets
Live virus (JR-FL or SIVmac251) was cultured in activated
human PBMC. Virus was mixed with graded concentrations of
Ab for 1 h at 37 °C. Mixtures were then added to fresh activated
PBMC and cultured for 3 days. The structural proteins p24 or
p27 were detected by ELISA, as described previously
(Hammonds et al., 2005).
Trimer binding in native PAGE
We measured the ability of antibodies to bind VLP-derived
Env trimers, based on the premise that trimer–Ab complexes
migrate more slowly than their unliganded counterparts in BN-
PAGE (Crooks et al., 2005; Moore et al., 2006). Specifically,
JR-FL 140T SOS-VLPs were incubated with HIV+ plasmas,
VLP sera and/or mAb b12 Fab for 15 min, followed by a wash.
Trimers were then resolved by BN-PAGE and Western blot.
Since the migration properties of trimer–Ab complexes can
vary, binding was measured by depletion of the unliganded
trimer. Using NIH Image software, a box was drawn around the
unliganded trimer band and the density was measured in
arbitrary units. The density of a control bands with no ligand
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unliganded trimer in lanes in which ligands were added.
Adsorption of sera against 293T cells
Sera were adsorbed against 293T cells to remove reactivity
against membrane-associated proteins (Giannecchini et al., 2001;
Langlois et al., 1992). Briefly, pellets containing 108 293T cells
were mixed with 200 μl of serum and mixed overnight at 4 °C.
Cells were then pelleted and the serum retrieved. The process was
repeated 2 more times. The supernatant serum was completely
cleared of cells and then assayed by ELISA to detect anti-gp120
Abs compared to unabsorbed sera to determine whether anti-
gp120 titers were affected by adsorption.
Flow cytometry
Guinea pig serum binding to 293T, CF2 and HOS cells was
assessed. Cells were incubated with sera at graded dilutions for
1 h at RT. An FITC conjugate (Jackson, West Grove, PA) was
used to detect guinea pig IgG binding by FACS.
Analysis of serum binding titer and specificity by ELISA
We measured anti-gp120 titers of guinea pig sera by ELISA,
as described previously (Binley et al., 1997). A goat anti-guinea
pig or human alkaline phosphatase conjugate (Accurate) was
used to detect bound Ab using the AMPAK system (Dako).
Reactivity against epitopes exposed on denatured gp120 was
measured against captured gp120 that had been treated with 1%
SDS and 50 mM DTT and boiled for 2 min and then diluted in
PBS before captured on D7324-coated plates. Peptide ELISAs
were performed in a similar manner.
Serum mapping by inhibition of mAb-virus capture
To determine the specificity of sera, we examined their
ability to inhibit JR-FLWT-VLP capture by a panel of mAbs, as
described previously (Derby et al., 2006). VSV-G was co-
expressed on particle surfaces to enhance detection of captured
virus and also to provide a read-out of capture that is essentially
unaffected by possible serum neutralization (Moore et al.,
2006). Briefly, mAbs were coated on ELISA microwells
overnight at 5 μg/ml. Wells were then washed and blocked
with 3% bovine serum albumin (BSA) in PBS. Graded dilutions
of sera were incubated with JR-FL WT-VLPs bearing VSV-G
for 30 min. For X5 mAb capture, a fixed concentration of 5 μg/
ml sCD4 was added throughout. Mixtures were then added to
mAb-coated ELISA wells for 3 h followed by washing with
PBS (Poignard et al., 2003). CF2.CD4.CCR5 cells (Kolchinsky
et al., 2001) were overlaid and 2 days later, infection was
measured by assaying luciferase.
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